4D Molecular Therapeutics (FDMT) Revenue (QoQ) (2020 - 2026)
4D Molecular Therapeutics (FDMT) Revenue (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.09% |
| Mar 31, 2026 | -96.42% |
| Dec 31, 2025 | 94,444.44% |
| Sep 30, 2025 | 500.00% |
| Jun 30, 2025 | 7.14% |
| Mar 31, 2025 | 1,300.00% |
| Dec 31, 2024 | -66.67% |
| Sep 30, 2024 | -40.00% |
| Jun 30, 2024 | -82.14% |
| Mar 31, 2024 | 247.37% |
| Dec 31, 2023 | -100.09% |
| Sep 30, 2023 | 8,353.56% |
| Jun 30, 2023 | -19.80% |
| Mar 31, 2023 | -76.10% |
| Dec 31, 2022 | 149.40% |
| Sep 30, 2022 | 208.64% |
| Jun 30, 2022 | -86.71% |
| Mar 31, 2022 | 1,225.00% |
| Dec 31, 2021 | -93.27% |
| Sep 30, 2021 | -90.63% |